Unilabs Reports Third Quarter 2015 Financial Results
17.11.2015 13:30 | Business Wire
Unilabs, one of Europe’s leading providers of clinical laboratory testing and medical diagnostic imaging services, announced further growth today, reporting that for the quarter ending 30 September 2015, revenue was €152.8m, compared to €141.7m in Q3 2014. The results show a significant and positive organic sales growth of 4.5% (CER†) leading to EBITDA growth vs Q3 2014 of 12.9%. This marks the 5th successive quarter of revenue growth, EBITDA growth and cost savings.
Other significant milestones in the last quarter include:
- Organic growth in net sales is up 7.0% (4.5% CER) driven by new customer wins and volume increases in both Laboratory and Imaging from existing business
- Securing retendered imaging contract in Norway with an annual revenue of €40M
- Second lab acquired in Portugal, expanding Unilabs’ local presence
- Further acquisitions planned for Q4 and continued negotiation with medium sized companies
Unilabs has the most comprehensive portfolio of diagnostic services in Europe, with a broad range of more than 2,500 diagnostic tests. It is a leading supplier of clinical laboratory testing and medical diagnostic imaging services for public and private health services and other customer groups across 10 European markets as well as operating in both Latin America (Peru) and the Middle East (Dubai). With more than 200 diagnostic contracts, Unilabs has over 125 laboratories & 350 customer service locations. In 2014, its laboratories carried out over 100 million laboratory tests and over 1 million radiology exams providing swift and accurate results to allow a wide range of healthcare professionals to make key treatment decisions.
Jos Lamers, Chief Executive Officer at Unilabs said, “Our Q3 results show further positive growth in what is so far an extremely successful year. Our focus for the rest of 2015 remains on winning new customers based on our quality & service levels instead of price reductions. We believe this will ultimately drive further sales growth with a positive impact on the bottom line. In addition, our cost leadership initiative has already exceeded the 2015 full year plan after 9 months.”
|€millions||Q3 Reported||Q3 CER|
|2014||2015||% change||2015 CER||% change|
|Adjusted EBITDA margin||13.9%||14.7%||81 bps||14.8%||92 bps|
Commenting on the financial performance Chief Financial Officer Karl-Erik Clausen said, “The reported 7.8% growth in revenue (versus Q3 2014) has been driven by new customer wins and volume increases in both Laboratory & Imaging. Another significant factor is that we have been successful in securing the retender of our imaging contracts in Norway (€40M in annual revenue).”
Organic growth in net sales continued its positive trend with an increase of 7.0% (4.5% CER) compared to Q3 2014.
Strong organic growth was driven by:
- Continued customer wins leading to volume growth in Switzerland
- Positive growth in our imaging business in Denmark
- Successful implementation of contracts like the Norrbottens läns landsting (NLL – Public Heath Department) in Sweden
- Healthy development of high margin disciplines such as Companion Diagnostics (CDx), Drug Development Services (DDS) and Pathology
The results reported today show €3.6m of cost savings in Q3. This means that the strategic cost saving initiative has already exceeded its full year plan of €10m after 9 months - it is now anticipated to deliver €14M by the end of the 2015.
The most recent savings have been driven by continued lab consolidation, implementing efficient procedures in our laboratories, procurement savings & the initial results of our benchmarking projects. Following the success of the cost leadership initiatives in 2014-2015, further cost reduction targets are being set for 2016 and beyond.
Merger and Acquisition Activities
Three acquisitions have already closed in 2015. This quarter, a second laboratory has been acquired near Porto, Portugal, which has reinforced our presence in this key market for Unilabs. Further acquisition targets in France and across Europe will close in Q4. Several discussions with medium-size targets in different regions are ongoing.
Overview and outlook
Summarising the results from this quarter and the outlook for the remainder of 2015, Mr Lamers commented, “Every week we hear stories from our employees and customers who tell us about how our services remain at the heart and start of effective treatment decisions that positively impact people’s health & wellbeing. As a company, we are extremely motivated by this critical contribution to healthcare and the financial performance of our business is a reflection of the work all our people do to deliver a great service. We expect the current success to continue into the final quarter of 2015.”
*EBITDA: Earnings Before Interest, Taxes, Depreciation and Amortization
†CER: Constant Exchange Rates
Notes to Editors
Unilabs aspires to be at the heart and start of all effective treatment decisions. With over 125 laboratories and a broad catalogue of more than 2,500 diagnostic tests, Unilabs is one of Europe’s leading providers of clinical laboratory testing and medical diagnostic imaging services. Headquartered in Geneva, the Unilabs Group services sectors ranging from private and public healthcare providers to local governments, from pharmaceutical companies to the general public.
Unilabs mediates care. In 2014, its laboratories carried out over 100 million diagnostic tests ensuring swift, accurate diagnosis of patient samples, 5,000 IVF procedures and over 1 million radiology exams.
The importance of medical diagnostics is expanding; as focus shifts from treatment to prediction and prevention, and innovations in molecular and genetic testing continue to emerge, Unilabs aims to be at the heart of this healthcare transformation.
Unilabs Group employs more than 5,000 people worldwide, successfully operating laboratory and medical diagnostic imaging facilities in 12 countries. Its network of facilities provides it with one of the broadest geographic footprints of any clinical laboratory and medical diagnostic services provider in Europe.
For more information about Unilabs, please visit www.unilabs.com.
Forward Looking Statement
This press release contains various “forward-looking statements” that reflect management’s current view with respect to future events and anticipated financial and operational performance. Forward-looking statements as a general matter are all statements other than statements as to historical fact or present facts or circumstances. The words “aim,” “anticipate,” “assume,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “guidance,” “intend,” “may,” “plan,” “potential,” “predict,” “projected,” “risk,” “should,” “will” and similar expressions or the negatives of these expressions are intended to identify forward-looking statements. Other forward-looking statements can be identified in the context in which the statements are made. These forward-looking statements may include, among other things, statements relating to: our future financial position; our strategy and outlook; our liquidity, capital resources and capital expenditure; our planned investments; acquisition opportunities in the markets in which we currently, or may in the future, operate; expectations as to future growth in demand for our products and services; demographic trends; general economic trends and other trends in our industry; the impact of regulations on us and our operations; the competitive environment in which we operate; the outcome of legal proceedings; extreme weather conditions in the markets where we operate; failure to comply with privacy laws; and failure to comply with environmental health and safety laws. Although we believe that the expectations reflected in such forward-looking statements are reasonable, we can provide no assurances that such expectations will prove to be correct and such statements are not guarantees of future performance because they are based on numerous assumptions. Forward-looking statements are based on information available at the time those statements are made and management's good faith belief as of that time with respect to future events and are subject to known and unknown risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. For a further discussion of such risks please see the risks discussed under the caption “Risk Factors” beginning on page 26 of the Offering Memorandum dated July 10, 2013 (the “OM”) in connection with our offering of senior secured notes and second lien PIK toggle notes (collectively, the “Notes”). You should not place undue reliance on any forward-looking statement. Any forward-looking statement speaks only as at the date on which it is made and we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For further information or to arrange an interview with Unilabs CEO Jos
Lamers and/or CFO Karl-Erik Clausen:
Clark Health Communications
T: +44 (0)207 492 1900
Further investor relations information is available by registering at www.unilabs.com/investors
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Biker Summer 2017 campaign: What’s happening during Biker Summer 2017? Moto-tyres.co.uk is giving away exciting prizes!18.8.2017 09:22 | Pressemelding
Whether it’s a short weekend break or a long-distance tour – once again this year Moto-tyres.co.uk is asking bikers from 10 countries about their dream destinations and longest journeys as part of its “Biker Summer 2017” campaign. To ensure than nothing gets in the way of your next tour, the two-wheeler tyre store from Delticom, Europe’s leading online tyre dealer, is entering anyone who completes the survey before 30 September 2017 into a prize draw to win some great biking accessories. Simply answer three short questions about your plans for bike tours this year (don’t forget to provide your name and email address), and with a bit of luck, you might win one of these great prizes. Up for grabs are a GARMIN motorbike GPS system, a GoPro camera with helmet bracket and five 200-Pound vouchers for new motorbike tyres from the online store – thanks to the product range at Moto-tyres.co.uk, eve
Lenovo Continues to Gain Momentum in First Quarter FY 2017/1818.8.2017 00:04 | Pressemelding
Behind the strength of its 3-wave strategy, Lenovo’s business transformation continued to gain traction during the first quarter, delivering solid profitability in its core PC and smart devices business, and revenue and profit improvements in targeted growth areas, including the data center and mobile businesses. Fueled by new investments in people and products, Lenovo’s Data Center Group (DCG) introduced the most comprehensive product lineup in its history, with the new ThinkSystem and ThinkAgile portfolio, and continued to build out its end-to-end sales organization. Similarly, Lenovo’s Mobile Business Group launched significant new products led by the Moto Z2 Force, available now on all major U.S. carriers, and ramped up its branding efforts worldwide. “In the first quarter this fiscal year, we had stable performance as we executed our 3-wave strategy with commitment. We
Spirent Tests Wi-Fi Network Performance with O2 at the Coca-Cola London Eye17.8.2017 15:57 | Pressemelding
Spirent Communications plc (LSE:SPT), today announced its Landslide E10 network test platform has been used with O2 to validate the Wi-Fi network performance and capacity at the Coca-Cola London Eye, before the launch of a new smartphone application last month. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170817005758/en/ Spirent Landslide E10 helped O2 validate Wi-Fi performance and capacity at the Coca-Cola London Eye, before the launch of a new smartphone application last month. (Photo: Busines Wire) Merlin Entertainments plc, operator of the London Eye, wanted to measure its Wi-Fi network performance, to ensure its infrastructure could provide an excellent experience for users of the new app, which puts increased demands on the Wi-Fi network. “The London Eye is a global attractio
Watch BizWireTV: A Camera You Can Wear and Krispy Kreme’s Famous Donuts Get Eclipsed with Chocolate17.8.2017 12:08 | Pressemelding
On BizWireTV, catch some Quick Biz Hits and see the latest in Star Power. Also see what’s happening in the startup world with the Accelerator Report, featuring the VC Watch and this week’s Startup Standout. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170817005305/en/ BizWireTV is hosted by Jordyn Rolling (Photo: Business Wire Now you can watch BizWireTV, and the latest breakthroughs in tech from the biggest brands, on any screen you want by downloading the new app through the Apple TV and iPhone App Store and Google Play for Android devices. Top of the Wire Introducing FrontRow: the camera re-invented. Watch BizWireTV to see more disruptors as well as the top 5 trending stories of the week! A core c
PsiOxus Therapeutics Announce Two New Board Appointments: New Board Appointments Strengthen Company’s US Presence17.8.2017 07:00 | Pressemelding
PsiOxus Therapeutics, Ltd. (PsiOxus) today announced the appointment of Charles Rowland and Duncan Higgons to the Board of Directors as part of an ongoing drive to expand in the US. Charles Rowland was most recently the President and Chief Executive Officer (CEO) of Aurinia Pharmaceuticals, a clinical stage pharmaceutical company focused on the global lupus nephritis market. Prior to this, he served as the Vice President and Chief Financial Officer (CFO) of ViroPharma, during which time the company grew into a global biopharmaceutical business with $500 million in annual revenues until it was acquired by Shire plc for $4.2 billion. Before joining ViroPharma, Mr. Rowland was executive Vice President, CFO, and interim co-CEO, for Endo Pharmaceuticals. In his earlier career, Charles held finance and operational positions at Biovail Pharmaceuticals, Breakaway Technologies, Pharmacia
Smarsh Adds Voice Archiving Offering with Acquisition of London-Based Cognia17.8.2017 06:59 | Pressemelding
Smarsh®, providing information archiving solutions for compliance, e-discovery and risk management, has completed the acquisition of Cognia, a worldwide leader in cloud-based voice archiving, audio search and analytics. Smarsh will leverage Cognia’s intellectual property and development resources to offer its global customer base enhanced capabilities around mobile and fixed-line voice communication – alongside a market-leading range of electronic communications – within The Archiving Platform. The acquisition will expand the existing presence of Smarsh in Europe and is central to its MiFID II compliance solution for financial firms. In addition to capturing incoming and outgoing communication from fixed-line recording solutions, Cognia uniquely captures voice content directly from leading mobile carriers. Carrier-direct capture is the most reliable and automated method for capt
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom